---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-309581"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2022-12-21T23:59:59+00:00"
generated_at: "2026-06-21T00:41:44.885857+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jazz exercises zanidatamab option; pays $325M; 41.3% ORR in BTC trial

## Summary
- Jazz exercised option to retain exclusive rights to zanidatamab in U.S., Europe, and Japan.
- One-time $325M payment in Q4 2022; total potential milestones up to $1.76B plus royalties.
- Pivotal HERIZON-BTC-01 trial showed 41.3% ORR (95% CI: 30.4-52.8) and median DOR 12.9 months.
- Safety profile consistent with prior monotherapy; no new safety signals.
- Zymeworks eligible for tiered royalties of 10-20% on Jazz net sales pending approval.

## SEC filing metadata
- accession: 0001193125-22-309581
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2022-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312522309581/0001193125-22-309581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312522309581/d439594d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-309581
- JSON: https://secwatch.observer/filing/0001193125-22-309581.json
- Plain text: https://secwatch.observer/filing/0001193125-22-309581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.